|Table of Contents|

Short-term efficacy of bevacizumab combined with vinorelbine in the treatment of patients with recurrent metastatic cervical cancer as second-line drugs

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 03
Page:
451-454
Research Field:
Publishing date:

Info

Title:
Short-term efficacy of bevacizumab combined with vinorelbine in the treatment of patients with recurrent metastatic cervical cancer as second-line drugs
Author(s):
Lu Liang1; Liu Aihua2; Zhang Hanqun1; Cao Hui1; Li Xin1; Li Yong1
1.Department of Oncology，Guizhou Provincial People's Hospital，Guizhou Guiyang 550002，China；2.Guizhou Nursing Vocational College，Guizhou Guiyang 550002，China.
Keywords:
bevacizumab; vinorelbine; chemotherapy; cervical carcinoma
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2020.03.022
Abstract:
Objective：To observe the short-term efficacy and side effects of bevacizumab combined with vinorelbine in recurrent and metastatic cervical cancer patients.Methods：The clinical data of 34 patients with recurrent metastatic cervical cancer that were admitted to the Department of Oncology，Guizhou Provincial People's Hospital from January 2014 to December 2016，were retrospectively analyzed.All patients were treated with bevacizumab plus vinorelbine.In the 21-day cycle，chemotherapy was applied for 4 to 6 cycles.The efficacy and level of side effects were evaluated.Results：In the 34 patients with cervical cancer，0 had complete remission (CR)，7(20.6%) had partial remission (PR)，20(58.8%) had stable disease (SD)，and 7(20.6%) had disease progression（PD）.The effective rate (RR) was 20.6%(7/34) and the disease control rate(DCR) was 79.4%(27/34).34 patients with common adverse reactions of lesser extent can be tolerated.Conclusion：Bevacizumab combined with vinorelbine has a good short-term effect in patients with recurrent and metastatic cervical cancer，and its side-effect can be tolerated.Further studies are needed to evaluate the long-term efficacy and side effects of bevacizumab and viorelbine in recurrent and metastatic cervical cancer patients.

References:

［1］Liu FW，Cripe J，Tewari KS.Anti-angiogenesis therapy in gynecologic malignancies［J］.Oncology，2015，29(5)：350-360.
［2］Lhomme C，Vermorken JB，Mickiewicz E，et al.Phase II study of vinorelbine in patients with advanced and/or recurrent cervical carcinoma：An EORTC gynaecological cancer cooperative group study［J］.Eur J Cancer，2000，36(2)：194-199.
［3］Morris M，Brader KR，Burke TW，et al.Phase II study of vinorelbine in advanced squamous carcinoma of the cervix［J］.J Clin Oncol，1998，16(3)：1094-1098.
［4］Basu P，Jenson AB，Majhi T，et al.Phase 2 randomized controlled trial of radiation therapy plus concurrent interferon-alpha and retinoic acid versus cisplatin for stage III cervical carcinoma［J］.International Journal of Radiation Oncology Biology Physics，2016，94(1)：102-110.
［5］Tewari，Krishnansu S.Clinical implications for cediranib in advanced cervical cancer［J］.Lancet Oncology，2015，16(15)：1447-1448.
［6］Dong HS，Miseon K，Kyung HL，et al.Major clinical research advances in gynecologic cancer in 2017［J］.Journal of Gynecologic Oncology，2018，29(2)：1-18.
［7］Godoy OY，Plata J，Alcaide A，et al.Bevacizumab for recurrent，persistent or advanced cervical cancer：Reproducibility of GOG 240 study results in "real world" patients［J］.Clin Transl Oncol，2018，20(7)：922-927.
［8］Tewari KS，Sill MW，Long HJ，et al.Improved survival with bevacizumab in advanced cervical cancer［J］.N Engl J Med，2014，370(8)：734-743.
［9］Kitagawa R，Katsumata N，Shibata T，et al.Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer：The open-label randomized phase III trial JCOG0505［J］.J Clin Oncol，2015，33(19)：2129-2135.
［10］Muggia FM，Blessing JA，Method M，et al.Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix：A gynecologic oncology group study［J］.Gynecol Oncol，2004，92(2)：639-643.
［11］Coronel MD，Cetina MD，Cantu MD，et al.A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients［J］.International Journal of Gynecological Cancer，2013，23(5)：884-889.
［12］Zhan ZF，Kun L，Yong P，et al.Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer［J］.Medicine，2017，96(2)：e5853.
［13］Leone J，Perez JE，Dominguez ME，et al.Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimen［J］.International Journal of Gynecological Markers，2016，31(3)：e300-e308.
［14］Naotake T，Hidemichi W，Kimio U，et al.Chemotherapy and molecular targeting therapy for recurrent cervical cancer［J］.Chinese Journal of cancer Research，2016，28(2)：241-243.
［15］Tewari KS，Sill MW，Penson RT，et al.Bevacizumab for advanced cervical cancer：Final overall survival and adverse event analysis of a randomised，controlled，open-label，phase 3 trial (Gynecologic Oncology Group 240)［J］.Lancet，2017，390(10103)：1654-1663.
［16］Xiao Y，Cheng HJ，Wang L，et al.Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer［J］.European Journal of Gynaecological Oncology，2017，38(1)：76-79.
［17］Toru S，Mika M，Yoichi A，et al.A single-arm study evaluating bevacizumab，cisplatin，and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer［J］.Japanese Journal of Clinical Oncology，2017，47(1)：1-8.

Memo

Memo:
贵州省科技厅联合基金（编号：黔科合LH字［2016］7193）
Last Update: 1900-01-01